业务
货币单位:EUR
2025/Q3
名称营收比例
Research and development of PRAME-directed immunotherapies for the treatment of cancer518.7万100.00%
地区
货币单位:EUR
2024/FY
名称营收比例
BMS, United States7,809.9万50.12%
Moderna, United States6,278.5万40.29%
Genmab, Denmark1,495.1万9.59%